Skip to content
Screener

Alumis Inc. ALMS Business Segments — Operating Income

Similar metrics at other companies

Immunome logo
IMNMSingle Reportable — Operating Income
-$59.33M-32.9%
Capricor Therapeutics logo
CAPRSingle Reportable — Operating Income
-$36.77M-47.2%
LQD
LQDASingle Reportable — Operating Income
$61.5M+274%
Edgewise Therapeutics, Inc. logo
EWTXSingle Reportable — Operating Income
-$54.12M-17.7%
Theravance Biopharma logo
TBPHSingle Reportable — Operating Income
-$9.48M+34.3%
Ur-Energy logo
URGSingle Reportable — Operating Income
-$20.33M-28.4%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total research and development expense81,54096,622
General and administrative expenses18,61022,295
Total operating expenses100,150118,917
Loss from operations(98,409)(101,528)
Total other income (expense), net5,3562,565
Net loss before income taxes(93,053)(98,963)
Income tax benefit
Net loss$(93,053)$(98,963)

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s business segments — operating income?
Alumis Inc. (ALMS) reported business segments — operating income of -$98.41M in Q1 2026.
How has Alumis Inc.'s business segments — operating income changed year-over-year?
Alumis Inc.'s business segments — operating income increased by 3.1% year-over-year, from -$101.53M to -$98.41M.
What is the long-term trend for Alumis Inc.'s business segments — operating income?
Over 2 years (2023 to 2025), Alumis Inc.'s business segments — operating income has grown at a 69.4% compound annual growth rate (CAGR), from -$158.17M to -$453.8M.
What does business segments — operating income mean?
Calculated as revenue minus total operating expenses, representing the profitability of the company's core business activities. For clinical-stage companies, this is typically negative, reflecting significant investment in future product development.

Ask your AI about Alumis Inc.'s business segments — operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude